Risk Factors, Antithrombotic Management, and Long-Term Outcomes of Patients Undergoing Endovascular Treatment of Unruptured Intracranial Aneurysms

Abstract

Background Patients receiving endovascular treatment for unruptured intracranial aneurysms (UIAs) face varying risks and benefits with antithrombotic management. This study aimed to evaluate the perioperative and long-term effects of antithrombotic strategies, identify the populations that would benefit, and explore the predictive factors affecting the long-term outcomes.

Methods UIA patients undergoing endovascular treatment including stent-assisted coiling or flow diversion between June 2019 and June 2022 were enrolled. We compared perioperative and long-term complications between tirofiban and dual antiplatelet therapy groups. Optimal candidates for each antithrombotic treatment were identified using multivariate logistic regression. Nomograms were developed to determine the significant predictors for thromboembolic complications during follow-up.

Results Among 181 propensity-score matched pairs, the tirofiban group showed a trend toward a lower rate of thromboembolic complications than the DAPT group without elevating major bleeding risk in either period. Homocysteine (Hcy) level ≥10 μmol/L was a significant independent factor associated with thromboembolic complication in both periods. Subgroup analysis highlighted that in patients with high Hcy levels, tirofiban and sustained antiplatelet treatment for ≥12 months were protective factors, while a history of stroke was an independent risk factor for thromboembolic events in follow-up. Four variables were selected to construct a prognostic nomogram, history of hypertension, prior stroke, Hcy level, and the duration of antiplatelet therapy.

Conclusion Perioperative low-dose tirofiban and extended antiplatelet therapy demonstrated a favorable trend in long-term outcomes for UIA patients with preoperative Hcy levels ≥10 μmol/L undergoing endovascular treatment. The prognostic model offers reliable risk prediction and guides antithrombotic strategy decisions.

Keywords

unruptured intracranial aneurysms - endovascular treatment - antithrombotic strategies - long-term outcomes

^* These authors contributed equally as corresponding authors.

Publication History

Received: 07 February 2024

Accepted: 15 June 2024

Accepted Manuscript online:
18 June 2024

Article published online:
07 July 2024

• References

• 1 Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2019; 4 (04) CD004827
• 2 Brinjikji W, Murad MH, Lanzino G, Cloft HJ, Kallmes DF. Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis. Stroke 2013; 44 (02) 442-447
• 3 Zammar SG, Hamade YJ, El Ahmadieh TY, El Tecle NE, Bendok BR. Pitfalls and complications management in the endovascular treatment of aneurysms. Neurosurg Clin N Am 2014; 25 (03) 405-413
• 4 Hwang G, Huh W, Lee JS. et al. Standard vs modified antiplatelet preparation for preventing thromboembolic events in patients with high on-treatment platelet reactivity undergoing coil embolization for an unruptured intracranial aneurysm: a randomized clinical trial. JAMA Neurol 2015; 72 (07) 764-772
• 5 Saber H, Kherallah RY, Hadied MO, Kazemlou S, Chamiraju P, Narayanan S. Antiplatelet therapy and the risk of ischemic and hemorrhagic complications associated with Pipeline embolization of cerebral aneurysms: a systematic review and pooled analysis. J Neurointerv Surg 2019; 11 (04) 362-366
• 6 Wu Q, Shao Q, Li L. et al. Prophylactic administration of tirofiban for preventing thromboembolic events in flow diversion treatment of intracranial aneurysms. J Neurointerv Surg 2021; 13 (09) 835-840
• 7 Samaniego EA, Gibson E, Nakagawa D. et al. Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms. Stroke Vasc Neurol 2019; 4 (01) 36-42
• 8 Chalouhi N, Jabbour P, Daou B, Starke RM, Shields B, Hasan DM. A new protocol for anticoagulation with tirofiban during flow diversion. Neurosurgery 2016; 78 (05) 670-674
• 9 Calderón-Larrañaga A, Saadeh M, Hooshmand B. et al. Association of homocysteine, methionine, and MTHFR 677C>T polymorphism with rate of cardiovascular multimorbidity development in older adults in Sweden. JAMA Netw Open 2020; 3 (05) e205316
• 10 d'Emmanuele di Villa Bianca R, Mitidieri E, Di Minno MN. et al. Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. Proc Natl Acad Sci U S A 2013; 110 (39) 15812-15817
• 11 Catena C, Colussi G, Url-Michitsch M, Nait F, Sechi LA. Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension. J Am Soc Hypertens 2015; 9 (03) 167-175
• 12 Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Routledge; 1988: 567
• 13 Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD). Ann Intern Med 2015; 162 (10) 735-736
• 14 Thompson BG, Brown Jr RD, Amin-Hanjani S. et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention, American Heart Association, American Stroke Association. Guidelines for the management of patients with unruptured intracranial aneurysms: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46 (08) 2368-2400
• 15 Eskey CJ, Meyers PM, Nguyen TN. et al; American Heart Association Council on Cardiovascular Radiology and Intervention and Stroke Council. Indications for the performance of intracranial endovascular neurointerventional procedures: a scientific statement from the American Heart Association. Circulation 2018; 137 (21) e661-e689
• 16 Lessne ML, Shah P, Alexander MJ. et al. Thromboembolic complications after Neuroform stent-assisted treatment of cerebral aneurysms: the Duke Cerebrovascular Center experience in 235 patients with 274 stents. Neurosurgery 2011; 69 (02) 369-375
• 17 Fields JD, Brambrink L, Dogan A. et al. Stent assisted coil embolization of unruptured middle cerebral artery aneurysms. J Neurointerv Surg 2013; 5 (01) 15-19
• 18 Chalouhi N, Jabbour P, Kung D, Hasan D. Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms. Neurosurgery 2012; 71 (03) 710-714 , discussion 714
• 19 Delgado Almandoz JE, Kadkhodayan Y, Crandall BM, Scholz JM, Fease JL, Tubman DE. Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms. J Neurointerv Surg 2014; 6 (10) 767-773
• 20 Zi-Liang W, Xiao-Dong L, Tian-Xiao L. et al. Intravenous administration of tirofiban versus loading dose of oral clopidogrel for preventing thromboembolism in stent-assisted coiling of intracranial aneurysms. Int J Stroke 2017; 12 (05) 553-559
• 21 Giordano A, D'Angelillo A, Romano S. et al. Tirofiban induces VEGF production and stimulates migration and proliferation of endothelial cells. Vascul Pharmacol 2014; 61 (2–3): 63-71
• 22 Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J 2015; 14: 6
• 23 Santilli F, Davì G, Patrono C. Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: a mechanistic and clinical perspective. Vascul Pharmacol 2016; 78: 1-9
• 24 Jang EW, Kim YB, Chung J, Suh SH, Hong CK, Joo JY. Clinical risk factors affecting procedure-related major neurological complications in unruptured intracranial aneurysms. Yonsei Med J 2015; 56 (04) 987-992
• 25 Park JC, Lee DH, Kim JK. et al. Microembolism after endovascular coiling of unruptured cerebral aneurysms: incidence and risk factors. J Neurosurg 2016; 124 (03) 777-783
• 26 Ji W, Liu A, Lv X. et al. Risk score for neurological complications after endovascular treatment of unruptured intracranial aneurysms. Stroke 2016; 47 (04) 971-978